Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

#AANAM – Disease Severity, Job Loss Higher in Black Than White Patients in US

#AANAM – Disease Severity, Job Loss Higher in Black Than White Patients in US
3.3
(6)

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.

African Americans with relapsing-remitting multiple sclerosis (RRMS) are more likely than white patients — despite comparable disease durations and education levels — to be unemployed or earning less than $15,000 a year, and to have more severe disability, an analysis found.

And Hispanics in the U.S., especially Black Hispanics, are less likely to use disease-modifying MS treatments than are other racial or ethnic patient groups.

These findings “show disparities of sociodemographic and clinical characteristics of patients with MS,” said Victor Rivera, MD, a professor at Baylor College of Medicine, during their presentation at the annual meeting of the American Academy of Neurology (AAN), running online through April 22.

Rivera’s talk was titled, “Sociodemographic and Clinical Characteristics of Patients With Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry).” The analysis was funded by Biogen.

The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) is a physician-based registry with health and demographic data on MS patients between the ages of 18 and 50 in the U.S. and Canada.

Rivera presented clinical and demographic characteristics of 722 people added to this registry between late 2016 and mid-2020. These patients had a mean age of 40.1, and 71% were female.

Of the 695 patients living in the U.S., 84% were white and 11% were Black, and about a quarter were ethnically Hispanic. The amount of time since symptom onset and diagnosis was comparable between Black and white patients.

These two groups also had similar levels of education, but unemployment rates were significantly higher among Blacks (8% vs. 3%). Black MS patients were also significantly more likely to have an annual income of less than $15,000 compared with white patients (16% vs. 6%). Income rates were lowest among Black Hispanics than other racial or ethnic groups.

“Occupation and income status are disparate between Black/African American and white patients with MS, despite comparable educational attainment,” Rivera said.

Most of these patients (73%) had relatively mild disability, as evidenced by a score of 2.5 or lower on the Expanded Disability Status Scale (EDSS).

But rates of substantial disability — an EDSS score of 4.0 or higher — were more than twice as high among Black with RRMS than whites (21% vs. 10%). Hispanics had slightly higher substantial disability than did non-Hispanics (14% vs. 10%).

“Black/African American patients present with more severe MS-related disability than do white patients,” Rivera said.

A majority of this patient group, 57%, were treated with oral or injectable disease-modifying therapies (DMTs), or treatments proven in clinical trials to ease the course of MS.

Rates of DMT use, however, were significantly lower among Hispanics than non-Hispanics (43% vs. 62%), and lowest among Black Hispanics (26%) of all these racial or ethnic groups. Across ethnicities, rates of DMT use were lower among Black patients than whites.

“Fewer Hispanic than non-Hispanic patients with MS, and fewer Black/African American than white patients with MS, are treated with disease-modifying therapies,” Rivera concluded.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 81
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • Mavenclad and immune cells
  • therapeutic lag
  • Ocrevus update
  • Covid-19 and DMTs

How useful was this post?

Click on a star to rate it!

Average rating 3.3 / 5. Vote count: 6

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?